Mesoblast (MESO) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Broadcom Posts Strong Results, Joins RH, Upstart And Other Big Stocks Moving Higher On Friday
Benzinga12:21 ET
RFK Jr. Could Prove a Surprise Boon for Stem-cell Stocks With Pivotal Year Ahead
MarketWatchDec 12 12:08 ET
Stem Cells Poised for Success in 2025 as Regulatory Environment Looks More Favorable -- Market Talk
WSJDec 12 10:05 ET
Promising Developments and Regulatory Catalysts Highlight Mesoblast's Growth Potential
TipRanksDec 5 12:06 ET
Sector Update: Health Care Stocks Mixed Premarket Thursday
MT NewswiresDec 5 09:13 ET
SentinelOne, AeroVironment, PVH And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
BenzingaDec 5 08:34 ET

Comments

Stock_Drift

Dec 4 20:11

$Mesoblast (MESO.US)$

1

3

Trytosaveabit

Dec 4 17:56

News

$Mesoblast (MESO.US)$ FDA Grants Mesoblast's Revascor Regenerative Medicine Advanced Therapy Designation In Children With Congenital Heart Disease
Benzinga· 13 mins ago
Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the United States Food and Drug Administration (FDA) has granted its second generation allogeneic, STRO3-immunoselected, and industrially manufactured stromal cell therapy Revascor (rexlemestroc...

8

Jaguar8

Dec 2 18:05

🔴WATCHLIST Tuesday 12/3. NFA. Don’t open position without momentum. Use charts+indicators+order book. NO FOMO.

Note: This seems to be a long list. The rationale is that I al focused on at least 20% gains and not just after bangers. My trading style is to compound those 10-15-20-30% earnings and roll all profit rather than waiting for runners everyday. If runners appear, then I’ll grab it as well. Each has his own style earning.
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...

34

19

5

Jaguar8

Dec 2 17:23

NEWS

$Mesoblast (MESO.US)$
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced a key publication in the November 2024 online issue of the prestigious peer-reviewed European Journal of Heart Failure (EJHF), which reports that a single intramyocardial injection...

101674396

Nov 25 04:02

$Mesoblast (MESO.US)$ …got approval from FDA??

2

MESO Mesoblast

Trade Overview

Capital Trend

News

Comments